Рациональная фармакотерапия в кардиологии (Sep 2022)

Non-High Density Lipoprotein Cholesterol: A Modern Benchmark for Assessing Lipid Metabolism Disorders

  • S. A. Shalnova,
  • V. A. Metelskaya,
  • V. A. Kutsenko,
  • E. B. Yarovaya,
  • A. V. Kapustina,
  • G. A. Muromtseva,
  • G. E. Svinin,
  • Yu. A. Balanova,
  • A. E. Imaeva,
  • S. E. Evstifeeva,
  • V. G. Vilkov,
  • O. L. Barbarash,
  • O. A. Belova,
  • Yu. I. Grinshtein,
  • A. Yu. Efanov,
  • O. N. Kalachikova,
  • N. V. Kulakova,
  • O. P. Rotar,
  • I. A. Trubacheva,
  • D. V. Duplyakov,
  • R. A. Libis,
  • I. A. Viktorova,
  • A. N. Redko,
  • S. S. Yakushin,
  • S. A. Boytsov,
  • E. V. Shlyakhto,
  • O. M. Drapkina

DOI
https://doi.org/10.20996/1819-6446-2022-07-01
Journal volume & issue
Vol. 18, no. 4
pp. 366 – 375

Abstract

Read online

Aim. To perform a population analysis of Non-High Density Lipoprotein Cholesterol level (non-HDL-c) in Russian population and to evaluate its association with cardiovascular events.Material and Methods. The material consisted of results obtained from 11 regions of the ESSE-RF1 Study and from 4 regions of the ESSE-RF2 Study. Study protocols were identical. The studies were performed in 2012-2014 and 2017, respectively. Endpoints were assessed in 19041 people aged 35-64 years. The median follow-up was 6.5 years in ESSE RF (1) and 3.8 years in ESSE RF(2). Analysis was performed for three lipid variables: total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), and non-HDLC in two samples: the general population sample and the same sample without individuals with coronary heart disease (CHD), myocardial infarction (MI) and/or stroke history and not taking statins (the population sample of "without a history of cardiovascular diseases [CVD]". The analysis of nonlinear associations was performed using the generalized additive Cox model. The combined cardiovascular endpoint was represented by cardiovascular death and nonfatal MI and stroke. Traditional and laboratory FRs, socio-demographic parameters were analyzed. The significance level for all tested hypotheses was set to be 0.05.Results. The prevalence of elevated non-HDL-C level (>3.7 mmol/l) was found to be 74.6%. No gender differences were found: there was 74.6% for men and 74.5% for women. Both mean values and prevalence of elevated non-HDL-C were increased with age in women, and its level was slightly decreased in men after 55 years old. Almost all analyzed RFs were significantly associated with elevated non-HDL-C in these two population samples. In both samples elevated total CH and elevated LDL-C were associated with all-cause mortality after correction for all RFs. On the contrary, the non-HDL-C was associated with CVD combined end pints. It has been shown that the risk of these end points increases uniformly with increase in levels of non HDL cholesterol, no nonlinear associations were found.Conclusion. The results of a population-based analysis of non-HDL-C performed in the Russian population for the first time confirmed that elevated non-HDL-C levels contribute significantly to determining the risk of cardiovascular events in the medium term. It can be assumed that the new risk scales (SCORE2 and SCORE OP) proposed by the European Society of Cardiology and the European Society of Preventive Cardiology, which include non-HDL C instead of TC, will allow adequate assessment of 10-year cardiovascular risk for Russians. However, continued monitoring of endpoints in order to obtain stable associations is required.

Keywords